# Exelixis

Exelixis is an Asset Manager based in Alameda, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Alameda, United States
- **Region:** North America
- **Address:** Alameda, CA, United States
- **Founded:** 1994
- **Assets under management:** Undisclosed
- **Website:** www.exelixis.com
- **LinkedIn:** https://www.linkedin.com/company/exelixis

## Regulatory record

- **Reports private funds:** No

## About

Exelixis is a multi-platform cancer company. It advances biotherapeutics and small molecule programs for the treatment of cancer. The company develops new treatments for cancer patients and the people who care for them.

## Sectors

- Oncology
- Biotech
- Pharmaceuticals
- Small Molecule Therapies
- Biotherapeutics
- Antibody-Drug Conjugates

## People

- Michael M. Morrissey — President and CEO
- Jeffrey J. Hessekiel — EVP, General Counsel and Secretary
- P.J. Haley — EVP, Commercial
- Susan M. Hubbard — EVP, Human Resources
- Alan R. Shuldiner — EVP, R&D
- Art Krieg — EVP, Biotherapeutics and Scientific Innovation
- Tiffany L. Dass — EVP, Strategy and Corporate Affairs
- Christopher J. Senner — EVP, CFO

## Questions

### Who runs investment decisions at Exelixis?

Exelixis is a publicly traded biotech company, not a family office or asset manager. Strategic and capital allocation decisions are made by the CEO Michael Morrissey and the board of directors, all named on the corporate website. The firm allocates its internally generated cash flow to R&D pipelines, commercial infrastructure, and strategic partnerships rather than external fund-of-funds or direct deals outside oncology.

### How does Exelixis generate its capital?

Exelixis generates revenue from the commercial sales of its approved drugs, CABOMETYX (cabozantinib) and COMETRIQ (cabozantinib). These drugs treat advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. Licensing deals with Roche, Ipsen, and Takeda provide additional revenue outside the US. The company does not raise external fund capital.

### What investment stages does Exelixis target?

Exelixis does not invest in external startups or funds. Its own R&D pipeline spans from preclinical discovery (small molecule and biotherapeutics) through Phase III clinical trials and commercial launch. It does not operate an external venture capital arm or co-invest alongside other LPs.

### Which sectors does Exelixis explicitly avoid?

Exelixis focuses exclusively on oncology. It does not invest in other therapeutic areas such as cardiovascular, neurology, rare disease, or medical devices. The firm's pipeline is limited to small molecule inhibitors, antibody-drug conjugates, and bispecific antibodies all targeting cancer.

### Where is Exelixis headquartered?

Exelixis is headquartered at 1851 Harbor Bay Parkway, Alameda, CA 94502, in the San Francisco Bay Area. It also has a South San Francisco presence mentioned in earlier records. No other offices are disclosed.

## Related profiles

- [PaineWebber Group](https://altss.com/profile/painewebber-group)
- [Gismart Limited](https://altss.com/profile/gismart-limited)

---

Last updated: 2026-07-11T16:22:50.000Z

Canonical page: https://altss.com/profile/exelixis

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology